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Cartilage tissue engineering is arising as a technique for the repair of cartilage lesions in clinical applications. However,
fibrocartilage formation weakened the mechanical functions of the articular, which compromises the clinical outcomes.
Due to the low proliferation ability, dedifferentiation property and low production of cartilage-specific extracellular
matrix (ECM) of the chondrocytes, the cartilage synthesis in vitro has been one of the major limitations for obtaining
high-quality engineered cartilage constructs. This review discusses cells, biomaterial scaffolds and stimulating factors
that can facilitate the cartilage-specific ECM production and accumulation in the in vitro culture system. Special
emphasis has been put on the factors that affect the production of ECM macromolecules such as collagen type II
and proteoglycans in the review, aiming at providing new strategies to improve the quality of tissue-engineered
cartilage.
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Articular cartilage lesions, once caused by trauma or
pathology, are hard to heal by itself due to the poor cap-
ability of chondrocytes to regenerate. The treatment for
articular cartilage lesions is versatile and challenging,
which develops from initial microfracture, mosaicplsty
to the first (periosteum as the cover for the defects) and
second (collagen type I/III as the cover for the defects)
generation of autologous chondrocyte implantation (ACI)
and gradually widely used matrix-assisted autologous
chondrocyte implantation (MACI) [1,2]. The outcome of
the treatment improves with the development of the tech-
niques derived from cartilage tissue engineering. However,
there are always some cases with fibrocartilage repair in-
stead of hyaline cartilage regeneration, resulting in inferior
mechanical functions of the cartilage [3].
Cartilage is a special avascular and aneural tissue with
sparse chondrocytes embedding in the dense extracellular
matrix (ECM) and the cartilage ECM macromolecules
play a central role in cartilage functionality, primarily in* Correspondence: dapingwang1963@qq.com
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unless otherwise stated.the establishment of the mechanical functions [4]. Colla-
gen type II, proteoglycan and glycosaminoglycan (GAG),
as the primary compositions in the ECM, have always
been used as the criteria for the identification and evalu-
ation of the chondrogenic capacity of cells and constructs
obtained for cartilage tissue engineering. Parameters such
as GAG content, cell mobility and water content usually
can be reached up to the level of native tissue. However,
the quantity of collagen type II (the major molecule for
cartilage mechanical functions) is much lower from cells
in vitro than that from the native cartilage [5,6]. Therefore,
an obvious obstacle currently is the inadequate production
and accumulation of some chondrocyte-specific ECM
macromolecules, especially collagen type II in cultured
constructs comparing with native cartilage tissue, even
though there has been a great progression in regeneration
of the cartilage lesions using engineered constructs [5]. As
collagen type II to a large extent provides the tissue with
mechanical functions, strategies to promote its production
and accumulation in engineered tissues need to be stressed.
This review integrates cells, biomaterial scaffolds and
stimuli that can facilitate ECM production and accumu-
lation in cartilage tissue engineering (Table 1), with spe-
cial focus on their effects on collagen type II expression
and production. We endeavor to cover the above aspects
that can improve the quality and function of engineeredtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,











Collagens Type I/III Collagen, type II collagen [37-40]
Composite scaffolds PGA/fibrin, PLGA/PLLA, PLGA/collagen, peptide/gene modified scaffolds [41,42,44-50]
Novel scaffolds Nanofiber, Silicone rubber dish [51,52]
ECM-based scaffolds Cartilage/cell-derived ECM scaffolds [54-56]
Stimuli
Growth factors TGFβs, BMP2, IGF1, CCN2 [38,58-64]
Compounds Hydrocortisone, icariin, avocado [19,67-70]
Gene therapy BMPs, IGF1, TGFβs, miRNA, shRNA [20,21,38,65,72-76]
Environmental factors Hypoxia, pressure, bioreactor, cryopreservation [30,64,78-81,83-85]
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produce high-quality tissue engineered cartilage.
Cells
Cell sources
The cell sources employed in cartilage tissue engineering
range from chondrocytes, stem cells to gene-modified
cells. Several comparative studies revealed that chondro-
cytes cultured in vitro could produce more collagen type
II than that of its stem cell counterparts as the collagen
type II concentration was much higher in cultured chon-
drocytes [7,8]. Shahin et al. used human chondrocytes
for constructing tissue-engineered cartilage and the ob-
tained collage type II concentration was around 8.5% of
dry weight tissue. In contrast, in a similar study using
human adipose-derived stem cells, the concentration of
collagen type II was only 0.22% of dry weight tissue.
However, adipose-derived stem cells showed inferior
properties in chondrogenesis comparing with synovium-,
bone marrow- and periosteum-derived stem cells in both
human and rat [9,10]. Synovium-derived stem cells have
been proved to be superior for the production of cartil-
age matrix including collagen type II and have the great-
est ability for chondrogenesis, among the other stem cell
sources [1]. As for the comparison between chondro-
cytes and synovium-derived stem cells, there was a re-
search demonstrating synovium-derived stem cells and
BMSCs produced more GAGs and collagen than chon-
drocytes [11]. However, the chondrocytes used in the
research were P2 cells in monolayer culture (primary
culture was termed P0 here), of which the collagen type
II and aggrecan significantly decreased as shown in other
studies and also in our experiments using a rabbit model
(Additional file 1, Figure 1) [12,13]. Therefore, more in-
vestigations need to be explored for the verification.Nevertheless, a recent study showed that fibrocartilage-
like tissue produced from synovium-derived stem cells
was found in the superficial layer of cultured constructs
[14]. While in another study comparing human bone
marrow stromal cells (HBMSC) and articular chondro-
cytes, cartilage-like tissue derived from chondrocytes
was found in both superficial zone-like and middle
zone-like structure. By contrast, relatively thicker fibrous
capsules were shown in constructs from HBMSCs [15].
As superficial zone of the cartilage bears maximum load,
it needs to be paid special attention to in cartilage tissue
engineering. Chondrocyte and stem cells mentioned
above have been summarized in Table 2.
Sorted single cell clone and clonal cell strains were
also investigated for chondrogenic capacity. Fluorescence
sorted chondrocytes with brighter CD49c and CD44
were detected to expression more collagen type II and
higher levels of GAG than unsorted cells [16]. Magnetic-
ally sorted stromal cells (STRO-1) from human bone
marrow mononuclear populations have been used as
seed cells with alginate-chitosan encapsulating and were
proved to undergo chondrogenesis with increased colla-
gen type II and proteoglycan in micromass culture and
also in culture using a perfused bioreactor [17]. Induced
pluripotent stem cells (iPSCs) were also used for screen-
ing cells with high chondrogenic capacity. Fluorescence
sorted mouse fibroblast-derived iPSCs with GFP driven
by Col2 promoter/enhancer showed higher levels of col-
lagen type II, aggrecan and GAGs [18]. Therefore, iden-
tification of chondrocyte-specific markers and sorting of
cells with relatively higher chondrogenic capacity would
provide a new means for the seeding cells for cartilage
tissue engineering.
Gene-modified cells employed in cartilage tissue en-





Figure 1 Evaluation of GAGs, Col2a1 and aggrecan in passaged rabbit chondrocytes. (A-C) Toluidine blue staining showed production of
GAGs from cells declined following passaging from P0 (A), P1 (B) to P2 (C). Scale bar: 100 μm. (D-E) Real time PCR showed the expression of
Col2a1 (D) and aggrecan (E) decreased with cell passaging.
Table 2 Summary of chondrocyte and stem cells in the
part of cells
Cell type Species Passage Culture method Reference
Chondrocyte Human P2 Monolayer + 3D [7]
ADSC Human P4 Monolayer + 3D [8]
SDSC Human P2 Monolayer + 3D [11]
BMSC Human P2 Monolayer + 3D [11]
Chondrocyte Human P2 Monolayer [11]
Chondrocyte Rabbit P0-P4 Monolayer [12]
Chondrocyte Human P0-P4 Monolayer [13]
SDSC Human P4-P7 Monolayer + 3D [14]
Chondrocyte Human P0-P4 Monolayer + 3D [15]
BMSC Human P1-P4 Monolayer + 3D [15]
ADSC: adipose-derived stem cell; SDSC: synovium-derived stem cell; BMSC:
bone-marrow derived stem cell; Monolayer + 3D: monolayer culture followed
by 3D culture.
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technology, including cells with single gene transduction
and co-transduction of two genes or a gene with an
shRNA [19-21]. All these methods aim at improving the
chondrogenic capacity of cells and the quality of engi-
neered constructs. As for the details of genes and gene-
modified cells that can promote ECM synthesis and
collagen type II expression, they will be elucidated in the
later part of gene therapy.
Cell culture
Dedifferentiation is the major cause of degeneration of
chondrocytes in vitro and maintaining chondrocytes
phenotype and features is always on focus. Likewise, for
stem cells, chondrogenesis is the primary process to
chondrocytes and differentiation of stem cells has been
broadly investigated. Optimization of culture methods
improves characteristics of chondrocytes and facilitates
collagen type II and proteoglycan production in vitro.
There are various ways for chondrocytes culture and
chondrogenesis of stem cells, including using different
media, coating proteins and co-culture systems. Different
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be discussed later.
A study specifically designed to optimize the chondro-
genic medium using factorial design of experiments sug-
gested standard chondrogenic medium with increased
level of TGF-β1 and glucose and decreased level of dexa-
methasone could promote collagen type II to collagen
type I ratio (ColII/ColI) and better maintain the chondro-
cyte properties [22]. TGF-β1 in serum free medium has
been proved to increase collagen type II expression and
better maintain human chondrocyte phenotype compar-
ing with medium plus fetal calf serum (FCS) [23]. More-
over, the redifferentiation of serum free medium cultured
monolayer chondrocytes in a 3D scaffold was observed
with the expression of collagen type II and proteoglycans;
while it was not observed for chondrocytes and STRO-1
cells cultured in FCS supplemented medium [17,23,24].
One recent study showed chondrocytes cultured in
medium supplemented with 20% platelet-rich plasma pro-
duced thicker cartilage tissue than cells in medium with
20% FBS [25], suggesting platelet-rich plasma was more
able to maintain chondrocyte properties in vitro.
Different coatings of cell culture surfaces influences
chondrocyte culture in vitro. Cells cultured on collagen
type I and II coating dishes expressed more collagen
type II expression and produced more glycosaminogly-
can (GAG) than uncoated control samples [26,27].
Though not significantly, higher collagen type II expres-
sion was observed in chondrocytes on collagen type II
coated dishes than collagen type I coated dishes. On the
contrary, fibronectin was suggested to promote collagen
type II degradation [28]. More specific research came
from Shawn et al., who investigated the effects of coating
with zone-specific cartilage extracellular matrix molecules
on cartilage formation [29]. Cells cultured in monolayer
showed different outcomes with pellets culture. While
hyaluronic acid (HA) and osteopontin coating increased
Col2a1expression in monolayer culture, pellets culture of
cells harvested from HA coated dishes showed decreased
expression of collagen type II. On the contrary, tenascin C
promoted collagen type II expression in pellet culture
while inhibited its expression in monolayer culture. Cells
on type II collagen coated dishes showed consistent in-
creased expression of Col2a1 with both monolayer culture
and pellet culture system [29]. As different coatings and
different culture environments synergistically affect the
cell behaviors, both need to be taken into considerations
in an experimental design. Aside from protein coating,
TiO2-coated coverslips were used for human MSCs cul-
ture and proved to significantly enhance cell proliferation
without weakening the chondrogenic capacity [30], which
would also benefit the ECM production.
Cell co-culture systems have been used in many fields of
biomedical sciences. As for cartilage tissue engineering,co-culture of MSCs and chondrocytes provide us with a
means to obtain promising cells. After a comparative
study of chondrocytes, MSCs and co-culture of chondro-
cytes and MSCs, the co-cultured cells were suggested to
be the most prospective for cartilage tissue engineering
[31]. Co-culture of primary chondrocytes with MSCs or
embryonic stem cells or iPSCs increased collagen type II
and Sox 9 expression and promoted cartilage matrix for-
mation [3,32,33]. The optimal ratio of MSCs and chon-
drocytes in co-cultures for cartilage engineering varied in
different studies. Some study revealed that higher ratios of
human MSCs to human articular chondrocytes was more
beneficial to chondrogenesis as was shown by newly syn-
thesized cartilaginous ECM and collagen type II gene up-
regulation [34]. However, another study suggested 63:1 as
the appropriate initial ratio of MSCs/chondrocytes for
enough stable chondrocyte-like cells and the constructs
from co-cultures were more cartilaginous than that from
chondrocytes [35].
Development and optimization of cell culture methods
aiming at elevating the chondrogenic capacity of seed
cells will improve the cartilage-specific ECM production
and finally benefit the cartilage tissue engineering with
relatively higher quality of engineered constructs.
Scaffolds
There are various scaffolds used for cartilage tissue en-
gineering as a 3D environment facilitates to maintain
chondrocyte properties than monolayer culture. The
characteristics of a scaffold involve mechanical strength,
biocompatibility, biodegradability, porosity and toxicity
[36]. The scaffold must be structurally stable, allow cells
to infiltrate and growth factors to attach. All these char-
acteristics of scaffolds provide cells with healthy micro-
environment, beneficial cell-cell interaction and adequate
nutrient exchange in vitro. Thus, the constructs with cells
and ECM mimic the cartilage and are more close to the
native cartilage tissue than monolayer cells when im-
planted in the defects. Of so many scaffolds used, we will
focus on clinically used scaffolds and those assist to pro-
mote ECM production, especially collagen type II produc-
tion here.
Collagen is a major component in the cartilage matrix
and collagen scaffold has long been used for cartilage re-
pair [37]. Bilayer type I/III collagen membrane has been
clinically used worldwide for ACI and MACI and colla-
gen type II production and regeneration of hyaline-like
cartilage were obtained during the observations [38-40].
Collagen type II scaffold was also investigated for cartil-
age repair and in vivo study revealed newly formed car-
tilage structure the same with normal cartilage [41].
Fibrin glue was often limited to use due to its shrinking
feature in vivo. However, when it combined with polyur-
ethane, this new composite scaffold improved cell
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type II and also aggrecan [42]. Polyglycolic acid/fibrin
(PGA/fibrin) scaffolds used for chondrocyte culture also
enhanced the redifferentiation of ovine chondrocytes
and the induction of collagen type II and aggrecan after
culture. Biomechanical tests further supported this scaf-
folds for chondrocyte culture with a high tensile strength
of 3.6 N/mm2 [43]. Poly(L-lactic acid) (PLLA) and poly
(lactic-co-glycolic) acid (PLGA), as materials that have
been approved by the US Food and Drug Administration
for human clinical uses [44], have been often used for
the research of cartilage tissue engineering. Comparing
with PLLA, collagen type II and Arg-Gly-Asp (RGD)
peptide modified PLLA/PLGA (50:50), collagen type II
modified PLLA/PLGA (50:50) exhibits higher collagen
type II expression and shows superiority for chondro-
genesis both in vitro and in vivo [45]. Besides, based on
type I collagen-PLGA scaffold, improved funnel-like
collagen-PLGA hybrid scaffold was shown to be a stron-
ger promoter for cartilage regeneration [46]. PLGA scaf-
fold with hyaluronic acid incorporated substantially
promoted collagen synthesis [47]. Moreover, as PLGA
microspheres have been successfully used to immobilize
DNA, siRNA and growth factors [48,49]. Sox9 expres-
sion plasmid loaded PLGA microspheres have been in-
vestigated for chondrogenesis. Human MSCs seeded on
Sox9 gene and heparinized TGF-β3 coated dexameth-
sone loaded PLGA microspheres could drastically in-
crease collagen type II expression by 30 times compared
with control [50]. Therefore, gene incorporation pro-
vides a new and promising strategy to optimize the
property of scaffolds for tissue engineering.
Comparing with the traditional scaffolds, more and
more novel scaffolds have been under investigations, in-
cluding peptide-modified scaffolds and mobile scaffolds.
Mesenchymal stem cells cultured in Arg-Gly-Asp-Ser
(RGDS) peptide incorporated PEG-based hydrogels had
greater gene expression of collagen type II and produced
significantly more GAGs comparing with control [51]. A
newly designed synthetic link N peptide nanofiber was
suggested to remarkably promote collagen type II and
aggrecan production [52]. Since cell expansion would
lead to contact inhibition and to avoid the dedifferenti-
ation of chondrocytes through passaging, mobile scaffold
was also examined for chondrocyte culture. Differently
from traditional biomaterial scaffolds, the culture surface
area of the high-extension silicone rubber dish could in-
crease by 8 folds with a motorized device [53]. Thus, ad-
equate cells could be obtained and extracellular matrix
was simultaneously maintained, including collagen type
II, which would drastically decrease through passaging.
ECM-based scaffold is an emerging approach in the
field of cartilage tissue engineering in that it may be rela-
tively easy to retain the natural growth factors in theECM [54]. Cartilage-derived and cell-derived ECM scaf-
folds have been investigated and cartilage-like tissues
have been observed [55-57]. However, the quality of
formed cartilaginous tissue needs to be evaluated and
compared. With improvement of the ECM-based scaf-
fold, it would probably be a promising type of scaffolds
for cartilage tissue engineering.Stimuli
Growth factors and compounds
Various growth factors have been used for cartilage tis-
sue engineering. Members in TGF-β family have been
widely used to induce the chondrogenesis of MSCs and
enhance ECM synthesis. TGF-β3 was proved to be more
capable to induce chondrogenesis of MSCs and also in-
crease the expression of collagen type II and aggrecan
[41,58]. As for collagen type II production, the effect of
TGF-β1 used in different culture systems was controver-
sial. Depending on the design of the experiments, TGF-
β1 could either increase or decrease the expression of
collagen type II [59-61]. BMP-2 and IGF-1 both impact
chondrogenesis and promote collagen type II produc-
tion. In a study which compared the effects of BMP-2,
IGF-1 and their combination, BMP-2 treatment showed
superior ability for collagen type II expression than IGF-
1 [39]. Synergistical use of BMP-2 and BMP-7 gave better
outcome of ECM production [62]. A more recent study
showed standard chondrogenic medium plus TGF-β3,
BMP-2 and IGF-1 demonstrated stronger capability for
MSCs to produce collagen type II comparing with the
other three groups including standard medium with TGF-
β3 alone, TGF-β3 + BMP-2 and TGF-β3 + IGF-1 [63]. An-
other growth factor, connective tissue growth factor
(CCN2) has also been proved to strongly enhance the car-
tilaginous ECM production, including collagen type II and
was suggested to reduce age-related changes of articular
cartilage [64-67].
Besides the growth factors, some compounds are also
proved to effectively induce the expression of collagen
type II and other ECM proteins. Hydrocortisone has
been found to increase the ability of human articular
chondrocytes to produce ECM macromolecules and
icariin was proved to help the ECM synthesis in rabbit
articular chondrocytes [68-70]. Avocado/soybean unsa-
ponifiables was also identified to facilitate aggrecan and
collage type II expression in an osteoblast/chondrocyte
co-culture system [19]. Additionally, yeast hydrolysate
had been verified to be able to stimulate collagen type II
expression and inhibit MMP-13 production in chondro-
cytes, protecting the cartilage from degradation [71].
However, as for the mechanisms and their clinical use in
cartilage tissue engineering, further investigations need
to be performed.
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Gene therapy has been grown rapidly and is widely used
in biomedical sciences. Although gene therapy is in its
infancy for cartilage engineering, it shows promising to
contribute to the cartilage repair. Often, growth factors
are been transfected into chondrocytes or MSCs to im-
prove the properties of cells. IGF-1 and TGF-β1 have
been successfully transfected into articular chondrocyte
and BMSCs separately and both were proved to increase
the expression of collagen type II and aggrecan [20,72].
Meanwhile, functional study further demonstrated IGF-I
transfected implants accelerated the regeneration com-
pared with lacZ implants [20]. Furthermore, one recent
study investigating co-transduction of different gene
combinations which involved any two of genes IGF-1,
FGF-2, TGF-β1 and SOX-9 with adenovirus delivering
system showed that cells co-transduced with IGF-1 and
FGF-2 could significantly express higher aggrecan, colla-
gen type II and other ECM proteins than other combi-
nations [21].
In addition to delivering growth factors to cells to in-
crease cartilage-specific gene expression, down regulation
of some negative factors has also been proved to effect-
ively promote collagen type II and aggrecan expression.
MicroRNA-181b (miR-181b) has been identified to be a
negative modulator for cartilage development and siRNA
targeting miR-181b induced collagen type II expression
and significantly reduced degeneration of cartilage [73].
MiR-145 was proved to target Sox9 and suppress the
chondrogenesis of mesenchymal stem cells; while anti-
miR-145 inhibitor could rescue the expression of Col2a1,
aggrecan and relevant chondrogenic marker genes [74].
Besides, down regulation of some pro-inflammatory fac-
tors that could induce cartilage destruction, such as IL-1,
IL-6, TNF-α, would also help cartilage regeneration
[68,75,76]. Therefore, inhibition of the negative modulator
could be a promising therapeutic strategy for cartilage re-
generation. Furthermore, targeting chondrocyte COL1A1
with siRNA could significantly improve chondrocyte
phenotype, with increased ratio of COL2A1/COL1A1 and
improved cartilage-like matrix formation [39].
Furthermore, the combination of delivering growth fac-
tors and down-regulation of negative modulators has also
been investigated recently. Co-transduction of TGF-β3
with lentiviral transduction system and shRNA targeting
Col1a1 with adenoviral vectors demonstrated optimal effi-
cacy for collagen type II expression and cartilage forma-
tion [77]. As gene therapy is just arising in cartilage tissue
engineering, much needs to be explored in this field.
Environmental factors
As cartilage resides in a microenvironment with reduced
oxygen and various biomechanical stresses, creating a
similar environment in vitro may provide a way tomaintain the characteristics of chondrocytes. Hypoxia
with 5% or even 3% oxygen stimulated collagen type II
expression and biosynthesis of hyaline-like cartilage
matrix [39,78,79]. For dynamic environment, expression
of collagen type II and aggrecan were induced after the
stimulation of a uniaxial compressive load with 1kPa,
1Hz for 30 min [80]. Intermittent hydrostatic pressure
benefit long-term chondrocyte culture and the cartil-
aginous construct formation [81]. As for tensile strength,
abnormal cyclic tensile strain inhibited collagen type II
expression; while proper and cyclic tensile strain would
promote collagen type II expression [65,82]. To provide
an environment that could enhance nutrient transport
and maintain dynamic state for cells, bioreactors have
been used for cartilage tissue engineering. Combined
with scaffolds as the support for cells, the system facili-
tates chondrocyte proliferation and ECM accumulation
comparing with static culture [83,84]. Improved bioreac-
tor as wavy-wall bioreactor better increased the cartilage
matrix than common dynamic culture using spinner
flasks [84]. Perfusion bioreactor was also used to investi-
gate chondrogenesis and chondrocyte growth. It was
found that human articular chondrocytes within alginate
beads only produced collage type II in a perfused envir-
onment. Collage type II was not detected in the static
culture condition by contrast [17]. However, one prob-
lem caused by dynamic loading was less accumulation of
matrix in the scaffold as part of the newly synthesized
molecules would disperse into the medium [85]. Besides
dynamic environment mentioned above, cryopreservation
has a negative effect on the chondrogenic capacity of
chondrocytes. Human chondrocytes showed significantly
decreased collagen type II expression after cryopreserva-
tion [86]. Although new methods and scaffolds are being
under investigation for the preservation and revitalization
of articular cartilage or chondrocytes [87-89], it is better
to use freshly cultured chondrocytes for clinical applica-
tion if it is possible.
Conclusions
Cartilage tissue engineering mainly consists of seed cells,
scaffolds, stimuli and environmental factors. As cartilage
is more specific than other tissues with sparse chondro-
cytes and dense supportive ECM, emphasis should be
put on cell proliferation, differentiation and cartilage-
specific ECM production. Low proliferation ability and
dedifferentiation property of the chondrocytes limit fine
cartilaginous construct formation and use, as well as the
efficacy of current therapies. Through the selection of
cell sources, optimization of cell culture methods and
rise of innovative biomaterial scaffolds, tissue engineered
constructs with enhanced cartilage-specific ECM pro-
duction are promising in the near future. New technolo-
gies employing comprehensive factors may make the
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ical approaches from ACI, MACI to the ideal tissue-
engineered cartilage implantation (TEC).
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